BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19221150)

  • 1. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.
    Hotta K; Kiura K; Fujiwara Y; Takigawa N; Oze I; Ochi N; Tabata M; Tanimoto M
    Ann Oncol; 2009 May; 20(5):829-34. PubMed ID: 19221150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive-stage small-cell lung cancer--moving beyond response rate?
    Ferraldeschi R; Lorigan P
    Ann Oncol; 2009 May; 20(5):801-2. PubMed ID: 19403933
    [No Abstract]   [Full Text] [Related]  

  • 3. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
    Oze I; Hotta K; Kiura K; Ochi N; Takigawa N; Fujiwara Y; Tabata M; Tanimoto M
    PLoS One; 2009 Nov; 4(11):e7835. PubMed ID: 19915681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.
    Hotta K; Fujiwara Y; Kiura K; Takigawa N; Tabata M; Ueoka H; Tanimoto M
    J Thorac Oncol; 2007 May; 2(5):402-7. PubMed ID: 17473655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
    Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial.
    Hu X; Bao Y; Zhang L; Guo Y; Chen YY; Li KX; Wang WH; Liu Y; He H; Chen M
    Cancer; 2012 Jan; 118(1):278-87. PubMed ID: 21598237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for small-cell lung cancer.
    Metro G; Cappuzzo F
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):591-606. PubMed ID: 19694501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
    Amarasena IU; Walters JA; Wood-Baker R; Fong K
    Cochrane Database Syst Rev; 2008 Oct; (4):CD006849. PubMed ID: 18843733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
    Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
    Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
    Takahashi T; Yamanaka T; Seto T; Harada H; Nokihara H; Saka H; Nishio M; Kaneda H; Takayama K; Ishimoto O; Takeda K; Yoshioka H; Tachihara M; Sakai H; Goto K; Yamamoto N
    Lancet Oncol; 2017 May; 18(5):663-671. PubMed ID: 28343976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
    Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
    J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
    Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
    Halvorsen TO; Sundstrøm S; Fløtten Ø; Brustugun OT; Brunsvig P; Aasebø U; Bremnes RM; Kaasa S; Grønberg BH
    Acta Oncol; 2016 Nov; 55(11):1349-1354. PubMed ID: 27549509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as 
Second-line Treatment for Small Cell Lung Cancer].
    Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
    Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):658-666. PubMed ID: 30007803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
    Hotta K; Fujiwara Y; Matsuo K; Kiura K; Takigawa N; Tabata M; Tanimoto M
    J Thorac Oncol; 2009 Mar; 4(3):311-7. PubMed ID: 19190515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
    Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
    Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
    Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
    Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.